Elicio Therapeutics (ELTX) Cash from Financing Activities (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Cash from Financing Activities data on file, last reported at $8.0 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 22.28% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.4 million (down 17.37% YoY) and the FY2025 annual result came in at $36.7 million, down 13.29% from the prior year.
• Cash from Financing Activities climbed to $8.0 million in Q1 2026, from $4.9 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $30.8 million in Q3 2024 to a low of -$14000.0 in Q1 2022.
• A 5-year average of $8.6 million and a median of $8.8 million in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 100.01% — and 2023, when it jumped 71814.29%.
• Tracing ELTX's Cash from Financing Activities over 5 years: stood at $11.2 million in 2022, then tumbled by 37.36% to $7.0 million in 2023, then sank by 96.76% to $227000.0 in 2024, then jumped by 2042.29% to $4.9 million in 2025, then soared by 65.06% to $8.0 million in 2026.
• The last three Cash from Financing Activities figures came in at $8.0 million (Q1 2026), $4.9 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.